Blood cell diseases and thrombosis

Haematologica

Volumn 86, Issue 12, 2001, Pages 1236-1244

  Leone, G ^a   Sica, S ^a   Chiusolo, P ^a   Teofili, L ^a   De Stefano, V ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Acute leukemia; Chronic myeloproliferative diseases; Red cell membrane disorders; Thrombosis

Indexed keywords

ALKALINE PHOSPHATASE; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; ELASTASE; EPITOPE; PHOSPHATIDYLSERINE; THROMBOXANE;

CELL ACTIVATION; CELL ACTIVITY; DISEASE COURSE; DRUG MECHANISM; ENZYME RELEASE; LEUKOCYTE; MEGAKARYOPOIESIS; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOGENESIS; POLYCYTHEMIA VERA; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SICKLE CELL ANEMIA; THROMBOEMBOLISM; THROMBOGENESIS; THROMBOPHILIA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; ANIMAL; BLOOD; ERYTHROCYTE; HEMATOLOGIC DISEASE; HUMAN; METABOLISM; PATHOLOGY;

ANIMAL; ERYTHROCYTES; HEMATOLOGIC DISEASES; HUMAN; LEUKOCYTES; THROMBOSIS;

EID: 0035542765     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Uber eine neuen formbestandtheil des blutes und dessen rolle bei der thrombose und der blutgerinung
2. Overview of the thrombosis and its treatment
3. The interaction of leukocytes with platelets in blood coagulation
4. The damaging potential of leucocyte activation in the microcirculation
5. Leukocyte interaction with protein cascades in blood coagulation
6. The structural biology of expression and function of tissue factor
7. Initiation of coagulation by tissue factor
8. Simultaneous expression of tissue factor and tissue factor pathway inhibitor by human monocytes. A potential mechanism for localized control of blood coagulation
9. Recombinant tissue factor pathway inhibitor enhances the binding of factor Xa to human monocytes
10. Specific binding of soluble fibrin to macrophages
11. Activated platelets signal chemokine synthesis by human monocytes
12. Thrombospondin binds to monocytes-macrophages and mediates platelet-monocyte adhesion
13. Platelet glycoprotein lbα is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18)
14. The elastase-mediated pathway of fibrinolysis
15. Tissue factor expression by monocytes: Regulation and pathophysiological roles
16. Effect of human recombinant cytokines on the induction of macrophage procoagulant activity
17. Polymorphonuclear leucocytes modulate tissue factor prduction by mononuclear cells: Role of reactive oxygen species
18. Bidirectional modulation of platelet and polymorphonuclear leucocyte activities
19. Blood-borne tissue factor: Another view of thrombosis
20. The tissue factor pathway of blood coagulation
21. Isolation and characterization of cancer procoagulant: A cysteine proteinase from malignant tissue
22. Transfer of tissue factor from leukocytes to platelets is mediated by CD 15 and tissue factor
23. Platelet/polymorphonuclear leukocyte interaction in dynamic conditions: Evidence of adhesion cascade and cross talk between P-selectin and the β2 integrin CD11b/CD18
24. Enhancement of cathepsin G-induced platelet activation by leucocyte elastase: Consequente for the neutrophil-mediated platelet activation
25. Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony- stimulating factor
26. Leukocytes and the risk of ischemic heart disease
27. Role of red blood cells in thrombosis
28. The contribution of the haematocrit to thrombocytopenic bleeeding in experimental animals
29. Correction of the platelet adhesion defect in δ - Storage pool deficiency at elevated hematocrit: Possible role of adenosine diphosphate
30. Bleeding and thrombosis in myeloproliferative disorders
31. Thrombosis and hemorrhage in thrombocytosis evaluation of a large cohort of patients (357 cases)
32. Thromboembolic disease after splenectomy for hereditary stomatocytosis
33. Targeted inactivation of murine band 3 (AE1) gene produces an hypercoagulable state causing widespread thrombosis in vivo
34. Defective spectrin integrity and neonatal thrombosis in the first mouse model for severe hereditary elliptocytosis
35. Hematopoietic cells from β-spectrin-deficient mice are sufficient to induce thrombotic events in hematopoietically ablated recipients
36. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets
37. Endothelial cells in physiology and in pathophysiology of vascular disorders
38. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells
39. From efficacy to safety: A Polycythemia Vera Study Group report on hydroxyurea in patients with polycythemia vera
40. Polycythemia vera. A clinical study of 141 patients
41. Polycythemia Vera: The natural history of 1213 patients followed for 20 years
42. The effect of interferon α on myeloproliferation and vascular complications in polycythemia vera
43. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis
44. Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders
45. An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression
46. Clinical course of essential thrombocythemia in 147 cases
47. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia
48. Primary thrombocythemia
49. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera
50. No treatment for low-risk thrombocythemia: Results from a prospective study
51. Thrombosis free survival and life expectancy in 187 consecutive patients with essential thrombocythemia
52. Clonality analysis of hematopoiesis in essential thrombocythemia: Advantage of studying T lymphocytes and platelets
53. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications
54. Clonal hemopoiesis and risk of thrombosis in young female patients with essential thrombocythemia
55. Thrombotic complications in esssential thrombocythemia with relatevely low platelet counts
56. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis
57. Low dose aspirin in polycythaemia vera: A pilot study
58. Bleeding and thrombosis in myeloproliferative disorders
59. Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period
60. Budd-Chiari syndrome in chronic myeloid leukemia
61. Thrombotic thrombocytopenic purpura during interferon α treatment for chronic myelogenous leukemia
62. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders
63. High incidence of early thrombotic complications in patients with acute leukemia
64. Influence of genetic predisposition to thrombosis on natural history of acure promyelocytic leukaemia
65. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210 A variant, and further prothrombotic risk factors
66. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia
67. Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid
68. Problems existing in differentiation therapy of acute promyelocytic leukemia (APL) with all-trans retinoic acid (ATRA)
69. Effect of all-trans retinoic acid on procoagulant and fibrinolytic activities of cultured blast cells from patients with acute promyelocytic leukemia
70. Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia
71. All-trans-retinoic acid increases adhesion to endothelium of the human promyelocytic leukaemia cell line NB4
72. Incidence of thrombotic complications in adult patients with acute lymphoblastic leukemia receiving L-asparaginase during induction therapy: A retrospective study
73. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: Risk of thrombotic complications in L-asparaginase-induced antithrombin III deficiency
74. Thrombosis in children receiving L-asparaginase in acute lymphoblastic leukemia. Determining patients at risk
75. Thrombosis related to the use of L-asparaginase in adults with acute lymphoblastic leukemia: A need to consider coagulation monitoring and clotting factor replacement
76. Evidence of a hypercoagulable state in patients with acure lymphoblastic leukemia treated with low dose of E. coli L-asparaginase: A GIMEMA study
77. Negligible hemostatic toxicity of intermediate-dose Erwinase in adult patients with acute lymphoblastic leukemia: Preliminary data
78. Bleeding and thrombosis in children with acute lymphoblastic leukaemia, treated according to the ALL-BFM-90 protocol
79. Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. Coli asparaginase (COALL-92 and 97 protocols)
80. Natural history of paroxysmal nocturnal hemoglobinuria
81. Paroxysmal nocturnal haemoglobinuria: Long-term follow-up and prognostic factors
82. The molecular basis of paroxysmal nocturnal hemoglobinuria
83. Elevated levels of circulating procoagulant micropaticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia
84. Pathogenesis and treatment of sickle cell disease
85. Prothrombotic changes in children with sickle cell disease: Relationships to cerebrovascular disease and transfusion
86. Is there a correlation between raised erythropoietin and thrombotic events in sickle-cell anaemia?
87. Prothrombin mutant, factor V Leiden, and thermolabile variant of methylentetrahydrofolate reductase among patients with sickle cell disease in Brazil
88. Elevated prothrombin F1.2 fragment in sickle cell disease: Further evidente for activation of coagulation in the steady state
89. Thrombogenesis in sickle cell disease
90. Reduction of pain episodes and prothrombotic activity in sickle cell disease by dietary n-3 fatty acids
91. Hereditary spherocytosis, thrombocytosis, and chronic pulmonary emboli: A case report and review of the literature
92. Resistance to activated protein C in thalassaemic patients: An underlying cause of thrombosis
93. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia
94. Phosphatidylserine in the outer leaflet of red blood cells from b-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes
95. Fetal hemoglobin in sickle cell disease: Relationship to erythrocyte phosphatidylserine exposure and coagulation activation
96. Erythroid phosphatidyl serine exposure is not predictive of thrombotic risk in mice with hemolytic anemia
97. Cancer and venous thromboembolism: An overview
98. Autoimmune thrombophilic syndromes
99. Cytokines and hemostasis
100. Thrombophilia as a multigenic disease